Clinical trials: Transitional Cell Carcinoma of Urinary Bladder
Bladder Cancer
Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer
The purpose of this study is to find out the highest safe dose of the investigational drug CP-675,206 when given in combination with BCG therapy to patients who have experienced recurrent superficial bladder cancer after standard…
- Trial name
- NCT00880854
- Testing
- BCG and CP-675,206
- Sponsor
- University of Wisconsin, Madison
Urothelial Carcinoma
Derazantinib and Atezolizumab in Patients With Urothelial Cancer
The purpose of this study was to evaluate efficacy of derazantinib monotherapy or derazantinib-atezolizumab in combination in patients with advanced urothelial cancer harboring fibroblast growth factor receptor (FGFR) genetic…
- Trial name
- FIDES-02 (NCT04045613)
- Testing
- Derazantinib 300 mg once daily monotherapy, Derazantinib 200 mg once daily + atezolizumab 1200 mg, Derazantinib 300 mg once daily+ atezolizumab 1200 mg
- Where
- 66 sites in United States, Australia and 12 more
- Volunteers
- 95 people
- Sponsor
- Basilea Pharmaceutica
Bladder Cancer
Study of BCG + Aminophylline Toxicity When Used in the Treatment of Bladder Cancer
The purpose of this study is to evaluate whether a new potential treatment for non invasive bladder cancer is safe and if it leads to side effects such as irregular heart rate, agitation, or burning with urination.
- Trial name
- BCG (NCT01240824)
- Testing
- aminophylline
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Virginia
Urinary Bladder Neoplasm, Transitional Cell Carcinoma
CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood
Transurethral resection of bladder tumor (TURBT) is usually performed in a piecemeal technique. Tumor fragmentation and cell spilling could be responsible for high recurrence rates.
- Conditions
- Urinary Bladder Neoplasm, Transitional Cell Carcinoma, Urogenital Neoplasms, Circulating Tumor Cell
- Trial name
- NCT04811846
- Testing
- Bipolar transurethral resection of bladder tumor (TURBT), Bipolar transurethral plasma kinetic vaporization of bladder tumor (PKVBT)
- Where
- 2 sites in Austria
- Volunteers
- 40 people
- Sponsor
- University Teaching Hospital Hall in Tirol
Transitional Cell Carcinoma
Single Agent Abraxane as Second Line Therapy in Bladder Cancer
The purpose of this study is to determine what effects the drug Abraxane has on bladder cancer.
- Trial name
- NCT00683059
- Testing
- Paclitaxel
- Where
- 5 sites in Canada
- Volunteers
- 48 people
- Sponsor
- Sunnybrook Health Sciences Centre
Urothelial Carcinoma
Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer
Urothelial cancers of the bladder and upper urinary tract account for over 200,000 deaths and 600,000 diagnoses annually worldwide.
- Trial name
- UROSCOUT-1 (NCT06310759)
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 3,000 people
- Sponsor
- Tampere University Hospital
Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function
This phase II trial is studying how well giving gemcitabine, paclitaxel, and doxorubicin together with pegfilgrastim works in treating patients with metastatic or unresectable bladder cancer or urinary tract cancer and kidney…
- Conditions
- Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer
- Trial name
- NCT00478361
- Testing
- Gemcitabine hydrochloride, Paclitaxel, Doxorubicin hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Non Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Neoplasms
Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.
A database has been created and will be used in which data will be collected in electronic format relating to adult patients who underwent one of the following endoscopic resection surgeries: TURBK, MAPPING, TURBK SECOND LOOK…
- Conditions
- Non Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Neoplasms, Non-Muscle Invasive Bladder Urothelial Carcinoma, Bladder Cancer
- Trial name
- NCT06167356
- Where
- Italy
- Volunteers
- 20,000 people
- Sponsor
- IRCCS San Raffaele
Transitional Cell Carcinoma of the Bladder
Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder
This pilot study is designed to determine feasibility and safety of treatment with dasatinib administered orally once daily for 4 weeks duration prior to radical cystectomy for urothelial carcinoma of the bladder.
- Trial name
- NCT00706641
- Testing
- Dasatinib, Radical Cystectomy
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Hoosier Cancer Research Network
Bladder Cancer, Urothelial Carcinoma
Risk-Enabled Therapy After Initiating EV/Pembro for Bladder Cancer
RETAIN-3 is a phase II study in patients with cT2-T3N0M0 muscle-invasive urothelial carcinoma of the bladder. Participants will receive neoadjuvant enfortumab vedotin and pembrolizumab followed by clinical and biomarker-based…
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma, Muscle-invasive Bladder Urothelial Carcinoma
- Trial name
- RETAIN-3 (NCT07908979)
- Testing
- Enfortumab vedotin, Pembrolizumab, Cisplatin
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Fox Chase Cancer Center
Urothelial Carcinoma
Investigation and Detection of Urological Neoplasia in Patients Referred With Suspected Urinary Tract Cancer:
Bladder cancer is common in the UK and can kill. A common sign of bladder cancer is blood in the urine (haematuria). GPs will refer to a specialist (Urologist) for further investigation of haematuria if they suspect cancer.
- Trial name
- IDENTIFY (NCT03548688)
- Where
- United Kingdom
- Volunteers
- 11,059 people
- Sponsor
- British Urology Researchers in Surgical Training
Bladder Cancer, Ureter Cancer
Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy
This study aims to verify superiority of pemetrexed maintenance to observation for patient without disease progression after 1 st line cisplatin-based chemotherapy.
- Conditions
- Bladder Cancer, Ureter Cancer, Transitional Cell Carcinoma
- Trial name
- PREMIER (NCT03193788)
- Testing
- pemetrexed, Folic Acid, Vitamin B12 Injection
- Where
- 21 sites in South Korea
- Volunteers
- 74 people
- Sponsor
- Asan Medical Center
Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Bladder (Urothelial, Transitional Cell) Cancer
A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT
This is a Phase 3, open-label, randomized trial designed to evaluate the DFS of TURBT followed by NDV-1 (sustained-release gemcitabine-docetaxel) versus TURBT followed by surveillance for the treatment of participants with…
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Bladder (Urothelial, Transitional Cell) Cancer, Urothelial Carcinoma Bladder, Urologic Cancer
- Trial name
- BOOST (NCT07313891)
- Testing
- NDV-01 (sustained-release gemcitabine-docetaxel)
- Sponsor
- Relmada Therapeutics, Inc.
Bladder Cancer, Urethral Cancer
S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium
RATIONALE: Drugs used in chemotherapy, such as carboplatin, paclitaxel, gemcitabine, and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00055835
- Testing
- carboplatin, cisplatin, gemcitabine hydrochloride
- Where
- 92 sites in United States
- Volunteers
- 7 people
- Sponsor
- SWOG Cancer Research Network
Bladder Cancer, Ureter Cancer
Study of Genexol-PM in Patients With Advanced Urothelial Cancer Previously Treated With Gemcitabine and Platinum
Taxane-based chemotherapy is currently one of the most commonly used regimen for salvage chemotherapy in advanced urothelial carcinoma.
- Trial name
- NCT01426126
- Testing
- Genexol PM
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Asan Medical Center
Adenocarcinoma of the Bladder, Distal Urethral Cancer
Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
This phase II trial is studying how well sorafenib works in treating patients with progressive regional or metastatic cancer of the urothelium.
- Conditions
- Adenocarcinoma of the Bladder, Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer
- Trial name
- NCT00112905
- Testing
- sorafenib tosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Urothelial Carcinoma of the Urinary Bladder
Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder
The investigators intend to evaluate the safety and toxicity profile of intravesically administered multidrug regimen of Cabazitaxel, Cisplatin and Gemcitabine in treatment refractory Transitional Cell Carcinoma.The investigators…
- Trial name
- CGC (NCT02202772)
- Testing
- Cabazitaxel, Gemcitabine, Cisplatin
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Guarionex J. Decastro
Muscle-Invasive Bladder Carcinoma, Urothelial Carcinoma (UC)
Immune-Stromal Landscape in Muscle-Invasive Bladder Cancer
Bladder cancer is a significant global health issue. When the cancer spreads into the muscle layer of the bladder (muscle-invasive bladder cancer), a common treatment is the surgical removal of the bladder (radical cystectomy).
- Conditions
- Muscle-Invasive Bladder Carcinoma, Urothelial Carcinoma (UC), Bladder Cancer, Muscle-Invasive Urothelial Bladder Carcinoma
- Trial name
- NCT07525349
- Volunteers
- 100 people
- Sponsor
- Assiut University
Urothelial Carcinoma, Bladder Cancer
UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch
This comprehensive genomic analysis and biospecimen repository study incorporates Next Generation Sequencing (NGS) of archival tumor tissue from 200 subjects with metastatic urothelial cancer in support of several parallel goals.
- Conditions
- Urothelial Carcinoma, Bladder Cancer, Urethral Cancer, Cancer of the Ureter
- Trial name
- NCT02643043
- Testing
- Biospecimen Collection
- Where
- 8 sites in United States
- Volunteers
- 219 people
- Sponsor
- Matthew Milowsky, MD
Bladder Cancer
Transurethral Resection and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combination chemotherapy combined with transurethral resection may kill more tumor cells.
- Trial name
- NCT00003640
- Testing
- filgrastim, cisplatin, doxorubicin hydrochloride
- Where
- Italy
- Volunteers
- 73 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC